Rachel Thibodeaux
Endocrinology, Diabetes & Metabolism · Round Rock, TXNPI 1891067336
Payments from drug & device makers
Across 47 payments — averaging $21.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alpha Orthopedic Systems$167
- Dexcom, Inc.$113
- Lilly USA, LLC$92
- Medtronic$76
- Ascensia Diabetes Care US Inc.$49
- Amgen$44
- plus $477 from 21 others
What the payments were for
- Food & beverage$1,00699%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alpha Orthopedic Systems | 1 | $167 |
| Dexcom, Inc. | 7 | $113 |
| Lilly USA, LLC | 6 | $92 |
| Medtronic | 4 | $76 |
| Ascensia Diabetes Care US Inc. | 1 | $49 |
| Amgen | 2 | $44 |
| Mannkind Corporation | 2 | $38 |
| Corcept Therapeutics | 2 | $36 |
| Insulet Corporation | 2 | $35 |
| Novo Nordisk | 2 | $35 |
| Acella Pharmaceuticals, LLC | 2 | $34 |
| Zealand Pharma US, Inc. | 1 | $26 |
| Xeris Pharmaceuticals, Inc. | 1 | $25 |
| Alvogen Inc | 1 | $24 |
| Novartis | 1 | $23 |
| Antares Pharma, Inc. | 1 | $22 |
| IBSA Pharma Inc. | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Tolmar, Inc. | 1 | $18 |
| Amryt Pharma Holdings Ltd | 1 | $18 |
| Boehringer Ingelheim | 1 | $18 |
| Radius Health, Inc. | 1 | $17 |
| Bayer | 1 | $17 |
| Shockwave Medical, Inc | 1 | $16 |
| Azurity Pharmaceuticals, Inc. | 1 | $13 |
| Cequr Corporation | 1 | $11 |
| Tandem Diabetes Care, Inc. | 1 | $11 |
How this compares
$1,018 in reported general payments places this provider in the 30th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 21 | $24,955 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $13,798 |
| Tresiba Flextouch U-100Insulin Degludec | 12 | $9,394 |
| SynthroidLevothyroxine Sodium | 67 | $5,361 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $1,419 |
| Levothyroxine Sodium | 84 | $768 |
| Metformin Hcl ErMetformin Hcl | 60 | $677 |
| Liothyronine Sodium | 13 | $673 |
| Metformin Hcl | 40 | $500 |
| Atorvastatin Calcium | 39 | $365 |
| Ezetimibe | 12 | $360 |
| Glimepiride | 28 | $330 |
| Fenofibrate | 11 | $262 |
| Rosuvastatin Calcium | 14 | $192 |
| Amlodipine Besylate | 17 | $83 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $35 | $24,95521 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in Round Rock
- Hien TranRound Rock$3.6M
- Kerem OzerRound Rock$2.3M
- Stephanie ShawRound Rock$936K
- Julio RosenstockDallas$24.9M
- Michelle WelchShavano Park$17.3M
- Maria CabanillasHouston$16.4M
- Sumana GangiMesquite$13.2M
- Damaris VegaHouston$12.3M
- Mark KipnesSan Antonio$10.3M
- Amer Al KaradshehHouston$8.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.